Research Article


DOI :10.26650/IUITFD.1365883   IUP :10.26650/IUITFD.1365883    Full Text (PDF)

THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS

Özlem Kandemir AlibakanHasan Eruzunİlkim Deniz ToprakUğur YılmazMehmet Alptekin Acarİpek Bilge AslanMerve Polat OnmazYasemin GökdenYücel ArmanTufan Tükek

Objective: Nesfatin-1 is an anorectic polypeptide that plays im portant roles in regulating appetite and energy intake. Cachexia and malnutrition are common in individuals with cirrhosis. We ex amined the relationship between serum nesfatin-1 levels and stage of cirrhosis, with the hypothesis that an increase in nesfatin-1 levels in patients with cirrhosis may be related to this catabolic process.

Material and Method: The study includes 51 patients with cirrhosis and 30 healthy volunteers. Nesfatin-1 levels in serum samples were compared using the enzyme-linked immunosorbent assay (ELISA). We calculated the Child-Pugh stages and Model for End-Stage Liver Disease (MELD) scores of patients with cirrhosis and examined their relationship with nesfatin-1. We’ve also investigated the relationship between cirrhosis complications and nesfatin-1.

Results: We found nesfatin-1 levels to be significantly higher in the cirrhosis patient group compared to the control group (p=0.001). The patient group was divided into those with compensated and those with decompensated liver cirrhosis  and compared with the control group. Nesfatin-1 levels were found to be significantly higher in the compensated liver cirrhosis group (p=0.01). When classifying the patients with cirrhosis based on their Child-Pugh stages and MELD scores, no significant relationship was detected between these groups and their nesfatin-1 levels.

Conclusion: Nesfatin-1 may have antioxidant, anti-inflammatory, and anti-apoptotic effects in maintaining the state of patients with compensated liver cirrhosis. Low levels of nesfatin-1 in decompensated liver cirrhosis may result from defense mecha nisms and inadequate production.

DOI :10.26650/IUITFD.1365883   IUP :10.26650/IUITFD.1365883    Full Text (PDF)

KARACİĞER SİROZLU HASTALARDA SERUM NESFATİN-1 DÜZEYLERİNİN HASTALIK ŞİDDETİ VE KOMPLİKASYONLARI İLE İLİŞKİSİ

Özlem Kandemir AlibakanHasan Eruzunİlkim Deniz ToprakUğur YılmazMehmet Alptekin Acarİpek Bilge AslanMerve Polat OnmazYasemin GökdenYücel ArmanTufan Tükek

Amaç: Nesfatin-1, iştahın ve enerji alımının düzenlenmesinde önemli rolleri olan anorektik bir polipeptittir. Kaşeksi ve malnut risyon sirozlu bireylerde yaygındır. Nesfatin-1 düzeylerinin siroz lu hastalardaki artışının sirozdaki katabolik süreçle alakalı olabi leceği hipoteziyle nesfatin-1 serum düzeyleri ve siroz aşamaları ilişkisini inceledik.

Gereç ve Yöntem: Çalışmamıza 51 sirozlu hasta ve 30 sağlıklı gönüllü alındı. Serum örneklerinden nesfatin-1 düzeyleri ELISA kullanılarak karşılaştırıldı. Sirozlu hastaların Child-Pugh evreleri ve multifaktöriyel son dönem karaciğer hastalığı modeli (MELD) skorları hesaplanarak nesfatin-1 ile ilişkileri incelendi. Ek olarak siroz komplikasyonları ile nesfatin-1 arasındaki ilişki araştırıldı.

Bulgular: Nesfatin-1 düzeyleri sirozlu hasta grubunda kontrol grubuna göre anlamlı olarak yüksek bulundu (p=0,001). Hasta grubu kompanse ve dekompanse olarak ayrılıp, kontrol grubu ile karşılaştırıldı. Kompanse siroz grubunda nesfatin-1 düzeyleri an lamlı olarak yüksek bulundu (p=0,01). Sirozlu hastalar Child-Pugh  evrelerine ve MELD skorlarına göre sınıflandırıldığında bu gru plar ile nesfatin-1 düzeyleri arasında anlamlı bir ilişki saptanmadı.

Sonuç: Sirozlu hastalarda kompanze halin sürdürülmesinde nes fatin-1’in antioksidan, antiinflamatuar ve antiapoptotik etkileri olabilir. Dekompanse sirozda nesfatin-1 düzeylerinin düşük olması savunma mekanizması ve yetersiz üretimden kaynaklanabilir.


PDF View

References

  • 1. Moctezuma-Velazquez C, Garcia-Juarez I, Soto-Solis R, Hernandez-Cortes J, Torre A. Nutritional assessment and treatment of patients with liver cirrhosis. Nutrition 2013;29:1279-85. [CrossRef] google scholar
  • 2. Traub J, Reiss L, Aliwa B, Stadlbauer V. Malnutrition in patients with liver cirrhosis. Nutrients 2021;13(2):540. [CrossRef] google scholar
  • 3. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443(7112):709-12. [CrossRef] google scholar
  • 4. Psilopanagioti A, Nikou S, Papadaki H. Nucleobindin-2/ nesfatin-1 in the human hypothalamus is reduced in obese subjects and colocalizes with oxytocin, vasopressin, melanin-concentrating hormone, and cocaine-and amphetamine-regulated transcript. Neuroendocrinol 2019;108(3):190-200. [CrossRef] google scholar
  • 5. Prinz P, Stengel A. Nesfatin-1: current status as a peripheral hormone and future prospects. Curr Opin Pharmacol 2016;31:19-24. [CrossRef] google scholar
  • 6. Xu Y, Chen F. Antioxidant, anti-inflammatory, and anti-apoptotic activities of nesfatin-1: a review. J Inflamm Res 2020;13:607-17. [CrossRef] google scholar
  • 7. Schalla MA, Stengel A. Current understanding of the role of nesfatin-1. J Endocr Soc 2018;2(10):1188-206. [CrossRef] google scholar
  • 8. Ogiso K, Asakawa A, Amitani H, Nakahara T, Ushikai M, Haruta I, et al. Plasma nesfatin-1 concentrations in restrictingtype anorexia nervosa. Peptides 2011;32(1):150-3. [CrossRef] google scholar
  • 9. Aydin F, Cindoglu C, Kirhan I, Uyanikoglu A, Yenice N. Serum prolidase, urotensin-2, and nesfatin levels in patients with compensated or uncompensated cirrhosis. Ann Med Res 2019;26(8):1666-9 [CrossRef] google scholar
  • 10. Di Pascoli M, Sacerdoti D, Pontisso P, Angeli P, Bolognesi M. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis. J Vasc Res 2017;54(2):92-9. [CrossRef] google scholar
  • 11. Frances R, Munoz C, Zapater P, Uceda F, Gascon I, Pascual S, et al. Bacterial DNA activates cell-mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004;53(6):860-4. [CrossRef] google scholar
  • 12. Úbeda M, Munoz L, Borrero MJ, Díaz D, Francés R, Monserrat J, et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology 2010;52(6):2086-95. [CrossRef] google scholar
  • 13. Özsavci D, Erşahin M, Şener A, Özakpinar ÖB, Toklu HZ, Akakín D, et al. The novel function of nesfatin-1 as an antiinflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats. Neurosurgery 2011;68:1699-708. [CrossRef] google scholar
  • 14. Yavuz M, Ozsoy M, Celep B, Gülsari Y, Aslan E, Bozbiyik O, et al. Anti-inflammatory and anti-apoptotic effect of nesfatin-1 on liver ischemia-reperfusion injury. Ann Ital Chir 2020;91:207-14. google scholar
  • 15. Thébault E, Purucker M, Whaler KA, Langlais B, Sabaka TJ. The magnetic field of the Earth’s lithosphere. Space Sci Rev 2010;155:95-127. [CrossRef] google scholar
  • 16. Kolgazi M, Ozdemir-Kumral Z, Cantali-Ozturk C, Demirci E, Yuksel M, Sirvanci S, et al. Anti-inflammatory effects of nesfatin-1 on acetic acid-induced gastric ulcer in rats: involvement of cyclo-oxygenase pathway. J Physiol Pharmacol 2017;68(5):765-77. google scholar
  • 17. Toprak İ, Eruzun H, Kutlu Y, Arman Y, Yumuştutan P, Yoldemir Aydın Ş, et al. Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock. J Exp Clin Med 2022;39(1):1-6. [CrossRef] google scholar
  • 18. Wernecke K, Lamprecht I, Jöhren O, Lehnert H, Schulz C. Nesfatin-1 increases energy expenditure and reduces food intake in rats. Obesity (Silver Spring) 2014;22(7):1662-8. [CrossRef] google scholar
  • 19. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am Physiol-Regul Integr Comp Physiol 2010;298(6):R1642-47. [CrossRef] google scholar
  • 20. Tanida M, Mori M. Nesfatin-1 stimulates renal sympathetic nerve activity in rats. Neuroreport 2011;22(6):309-12. [CrossRef] google scholar
  • 21. Başar Ö, Akbal E, Köklü S, Koçak E, Tuna Y, Ekiz F, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2012;72(6):479-83. [CrossRef] google scholar
  • 22. Ayyildiz T, Dolar E, Barbaros O, Arıkan Ş, Balaban S. Nonalcoholic Fatty Liver Disease and Its Association with Serum Nesfatin-1. Anatol Clin J Med Sci 2022;26(1):45-53. [CrossRef] google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Kandemir Alibakan, Ö., Eruzun, H., Toprak, İ.D., Yılmaz, U., Acar, M.A., Aslan, İ.B., Polat Onmaz, M., Gökden, Y., Arman, Y., & Tükek, T. (2024). THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS. Journal of Istanbul Faculty of Medicine, 87(3), 209-214. https://doi.org/10.26650/IUITFD.1365883


AMA

Kandemir Alibakan Ö, Eruzun H, Toprak İ D, Yılmaz U, Acar M A, Aslan İ B, Polat Onmaz M, Gökden Y, Arman Y, Tükek T. THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS. Journal of Istanbul Faculty of Medicine. 2024;87(3):209-214. https://doi.org/10.26650/IUITFD.1365883


ABNT

Kandemir Alibakan, Ö.; Eruzun, H.; Toprak, İ.D.; Yılmaz, U.; Acar, M.A.; Aslan, İ.B.; Polat Onmaz, M.; Gökden, Y.; Arman, Y.; Tükek, T. THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 87, n. 3, p. 209-214, 2024.


Chicago: Author-Date Style

Kandemir Alibakan, Özlem, and Hasan Eruzun and İlkim Deniz Toprak and Uğur Yılmaz and Mehmet Alptekin Acar and İpek Bilge Aslan and Merve Polat Onmaz and Yasemin Gökden and Yücel Arman and Tufan Tükek. 2024. “THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS.” Journal of Istanbul Faculty of Medicine 87, no. 3: 209-214. https://doi.org/10.26650/IUITFD.1365883


Chicago: Humanities Style

Kandemir Alibakan, Özlem, and Hasan Eruzun and İlkim Deniz Toprak and Uğur Yılmaz and Mehmet Alptekin Acar and İpek Bilge Aslan and Merve Polat Onmaz and Yasemin Gökden and Yücel Arman and Tufan Tükek. THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS.” Journal of Istanbul Faculty of Medicine 87, no. 3 (Nov. 2024): 209-214. https://doi.org/10.26650/IUITFD.1365883


Harvard: Australian Style

Kandemir Alibakan, Ö & Eruzun, H & Toprak, İD & Yılmaz, U & Acar, MA & Aslan, İB & Polat Onmaz, M & Gökden, Y & Arman, Y & Tükek, T 2024, 'THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS', Journal of Istanbul Faculty of Medicine, vol. 87, no. 3, pp. 209-214, viewed 15 Nov. 2024, https://doi.org/10.26650/IUITFD.1365883


Harvard: Author-Date Style

Kandemir Alibakan, Ö. and Eruzun, H. and Toprak, İ.D. and Yılmaz, U. and Acar, M.A. and Aslan, İ.B. and Polat Onmaz, M. and Gökden, Y. and Arman, Y. and Tükek, T. (2024) ‘THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS’, Journal of Istanbul Faculty of Medicine, 87(3), pp. 209-214. https://doi.org/10.26650/IUITFD.1365883 (15 Nov. 2024).


MLA

Kandemir Alibakan, Özlem, and Hasan Eruzun and İlkim Deniz Toprak and Uğur Yılmaz and Mehmet Alptekin Acar and İpek Bilge Aslan and Merve Polat Onmaz and Yasemin Gökden and Yücel Arman and Tufan Tükek. THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS.” Journal of Istanbul Faculty of Medicine, vol. 87, no. 3, 2024, pp. 209-214. [Database Container], https://doi.org/10.26650/IUITFD.1365883


Vancouver

Kandemir Alibakan Ö, Eruzun H, Toprak İD, Yılmaz U, Acar MA, Aslan İB, Polat Onmaz M, Gökden Y, Arman Y, Tükek T. THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS. Journal of Istanbul Faculty of Medicine [Internet]. 15 Nov. 2024 [cited 15 Nov. 2024];87(3):209-214. Available from: https://doi.org/10.26650/IUITFD.1365883 doi: 10.26650/IUITFD.1365883


ISNAD

Kandemir Alibakan, Özlem - Eruzun, Hasan - Toprak, İlkimDeniz - Yılmaz, Uğur - Acar, MehmetAlptekin - Aslan, İpekBilge - Polat Onmaz, Merve - Gökden, Yasemin - Arman, Yücel - Tükek, Tufan. THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS”. Journal of Istanbul Faculty of Medicine 87/3 (Nov. 2024): 209-214. https://doi.org/10.26650/IUITFD.1365883



TIMELINE


Submitted26.09.2023
Accepted28.04.2024
Published Online08.07.2024

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.